We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Bristol-Myers Squibb and Sanofi said they will appeal an $834 million judgment against them by a state court in Hawaii over the safety of their anti-blood clotting drug Plavix (clopidogrel). Read More
The World Health Organization (WHO)’s COVAX initiative is set to begin distributing vaccines to low- and middle-income nations this month, following the organization’s approval of an emergency-use listing of the AstraZeneca (AZ)/Oxford vaccine. Read More
The European Medicines Agency (EMA) is now reviewing Johnson & Johnson’s (J&J) conditional marketing authorization application for its COVID-19 vaccine, a single-dose inoculation that would help to simplify the EU’s vaccination efforts. Read More
Amgen has failed to convince the U.S. Court of Appeals for the Federal Circuit that Sanofi and Regeneron Pharmaceuticals should be made to pay for infringing its patents on its cholesterol drug Repatha (evolocumab). Read More
GlaxoSmithKline (GSK) has agreed to sell off its cephalosporin antibiotics product line to Novartis’ generics wing, Sandoz, for $350 million. Read More
Like other parts of the FDA, the Center for Drug Evaluation and Research had to scramble last year to address COVID-19 while not losing sight of its other important tasks, according to its latest annual report on Drug Safety Priorities. Read More
Efforts to reach large-scale production of a COVID-19 vaccine modified to address new viral variants could take AstraZeneca (AZ) at least six months to achieve, according to company documents. Read More
Roche’s anti-inflammatory drug Actemra (tocilizumab) has been shown to reduce COVID-19-related deaths in the UK’s RECOVERY trial of multiple potential treatments. Read More